XNAS · Healthcare · Biotechnology
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.02 | -0.01 | +50.00% | $51.8M | ✅ Beat | +1.21% | -10.76% | — |
| 2026-02-25 | Q4 2025 | -0.04 | -0.05 | -25.00% | $48.0M | ❌ Miss | +0.51% | -14.53% | -18.60% |
| 2025-11-05 |
| Q3 2025 |
| -0.04 |
| -0.03 |
| +25.00% |
| $47.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.03 | -0.02 | +33.33% | $49.0M | ✅ Beat | +2.50% | +2.88% | +0.72% |
| 2025-02-26 | Q4 2024 | -0.05 | -0.04 | +20.00% | $47.5M | ✅ Beat | +8.07% | +4.35% | +2.48% |
| 2024-11-07 | Q3 2024 | -0.08 | -0.04 | +50.00% | $28.3M | ✅ Beat | -0.93% | -13.52% | -7.23% |
| 2024-08-08 | Q2 2024 | -0.10 | -0.10 | +0.00% | $882,000 | ➖ Inline | +2.17% | -3.04% | -4.13% |
| 2024-05-02 | Q1 2024 | -0.10 | -0.09 | +10.00% | $304,000 | ✅ Beat | -0.51% | -1.77% | -3.04% |
Showing last 8 quarters.